Nurix Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nurix Therapeutics Inc 's ROA in the second quarter of 2026?
Nurix Therapeutics Inc recorded a cumulative net loss of $-341 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -57.32%.

However, within the Healthcare sector 599 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the May 31 2026 quarter, so far to 3911, from total ROA ranking in the first quarter of 2026 at 4513.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(May 31 2026) II. Quarter	(Feb 28 2026) I. Quarter	(Nov 30 2025) IV. Quarter	(Aug 31 2025) III. Quarter	(May 31 2025) II. Quarter
Y / Y Total Assets Change	-9.47 %	3.43 %	2.81 %	1.82 %	15.76 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-341	-295	-264	-245	-207
Return On Assets (TTM)	-57.32 %	-48.44 %	-43.76 %	-40.82 %	-34.71 %
NRIX's Total Ranking	# 3911	# 4513	# 3915	# 3865	# 3957
Total Assets (TTM) in million	536	636	688	522	592
Seq. Total Assets Change	-15.81 %	-7.56 %	31.71 %	-11.68 %	-3.82 %
Seq. Net Income Change	-	-	-	-	-

NRIX's 5 Years Annual ROA >> Back to NRIX Management Effectiveness >> Compare NRIX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 267
Sector	# 600
Overall	# 3969

Return On Assets Statistics
High	Average	Low
-15.23 %	-37.34 %	-57.32 %
(Feb 28 2021)		(May 31 2026)

Financial Statements
Nurix Therapeutics Inc 's Assets	$ 536 million	NRIX's Balance sheet
Nurix Therapeutics Inc 's Income	$ -90 million	Quarterly NRIX's Income Statement
NRIX's Income by Division		See NRIX's Income by Division

Annual Return On Assets	(Nov 30 2025) FY 2025	(Nov 30 2024) FY 2024	(Nov 30 2023) FY 2023	(Nov 30 2022) FY 2022	(Nov 30 2021) FY 2021
Y / Y Total Assets Change	2.81 %	88.23 %	-14.82 %	-12.43 %	20.29 %
Total Assets in million	688	669	356	417	477
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-264	-194	-144	-180	-117
Annual Return On Assets	-38.43 %	-28.92 %	-40.48 %	-43.2 %	-24.58 %

NRIX's 5 Years Annual ROA >> Back to NRIX Management Effectiveness >> Compare NRIX ROA to its Competitors

More Return On Assets Ratios
NRIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NRIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NRIX's Competitors
Subscribers only: Roa for Nurix Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for NRIX's Customers

You may also want to know
NRIX's Roi	NRIX's Inventory Turnover Ratio	NRIX's Growth Rates	NRIX's Dividend Comparisons
	NRIX's Profitability Ratios	NRIX's Asset Turnover Ratio	NRIX's Dividend Growth
NRIX's Roe	NRIX's Valuation Ratios	NRIX's Financial Strength Ratios	NRIX's Dividend Payout Ratio

Companies with similar Return On Assets at May 31 2026, within Healthcare Sector

ROA

Date modified: 2026-07-10T05:52:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.